ORUKA THERAPEUTICS INC

Oruka Therapeutics (ORKA) shows a bullish 20% above its 200‑day SMA, strong cash flow, and a promising heart‑failure pipeline—ideal for investors seeking precision‑medicine upside.

Oruka Therapeutics (ORKA) sees a 1.05% rise to $81.11 amid insider activity and a 15% decline since last month, while its genomic‑editing pipeline offers future upside.

Oruka Therapeutics’ stock surge masks insider selling, weak liquidity, and a shaky pipeline—investors should pause and watch for real progress.